Curanex Pharmaceuticals Inc
NASDAQ:CURX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Curanex Pharmaceuticals Inc
Other Current Assets
Curanex Pharmaceuticals Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Curanex Pharmaceuticals Inc
NASDAQ:CURX
|
Other Current Assets
$6.3m
|
CAGR 3-Years
1 415%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Assets
$4.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Assets
$1.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
6%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Assets
$2.8B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Assets
$9.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Assets
$14.5B
|
CAGR 3-Years
70%
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
Curanex Pharmaceuticals Inc
Glance View
Curanex Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Jericho, New York. The company went IPO on 2025-08-26. Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The firm is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The firm's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
See Also
What is Curanex Pharmaceuticals Inc's Other Current Assets?
Other Current Assets
6.3m
USD
Based on the financial report for Dec 31, 2025, Curanex Pharmaceuticals Inc's Other Current Assets amounts to 6.3m USD.
What is Curanex Pharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
1 415%
Over the last year, the Other Current Assets growth was 1 595%. The average annual Other Current Assets growth rates for Curanex Pharmaceuticals Inc have been 1 415% over the past three years .
